Skip to content

Clinical efficacy and safety of HuashiFengdu Granules in the treatment of superficial Cold and inner heat syndrome of influenza in children

Clinical efficacy and safety of HuashiFengdu Granules in the treatment of superficial Cold and inner heat syndrome of influenza in children

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069796
Enrollment
Unknown
Registered
2023-03-26
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

influenza

Interventions

treatment group:Huashuibaidu granules

Sponsors

Shenzhen Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 18 Years

Inclusion criteria

Inclusion criteria: (1) Meet the clinical diagnostic criteria for childhood influenza; (2) in line with traditional Chinese medicine children cold surface cold heat standards; (3) 3 ~ 18 years old (< 18 years old); (4) Duration of fever =48h, maximum axillary temperature =38.5?; (5) Rapid antigen test of influenza virus in throat swab was positive. (6) The informed consent process is in accordance with the regulations, and the legal agent or the tested children (=8 years old) sign the informed consent together.

Exclusion criteria

Exclusion criteria: (1) Severe or critical influenza cases, or diagnosed as pharyngeal conjunctive membrane fever, herpetic angina, suppurative tonsillitis, etc.; (2) influenza complications such as sinusitis, otitis media, bronchitis and pneumonia, etc.; (3) Antiviral drugs have been used within 48 hours prior to this visit; (4) had received influenza vaccine within 12 months before the trial began; (5) are systematically receiving steroid therapy or other immunosuppressive therapy; (6) A history of epilepsy or febrile convulsions; (7) patients with severe malnutrition, rickets and serious primary diseases of the heart, brain, liver, kidney and hematopoietic system; (8) Allergic to known ingredients of the test drug; (9) According to the judgment of the researchers, other diseases or conditions that reduce the possibility of enrollment or complicate enrollment, such as unstable living environment, inconvenient transportation and other conditions that could easily cause the loss of follow-up

Design outcomes

Primary

MeasureTime frame
Demographic data;General information;diadynamic criteria;Validity index and observation time point;

Countries

China

Contacts

Public ContactWan Lisheng

Shenzhen Children's Hospital

1875684406@qq.com+86 18938690468

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026